Group3_Production Planning for Pharmaceutical Company

7/24/2019 Group3_Production Planning for Pharmaceutical Company

1/16

Production Planning for

Pharmaceutical Company

Group 3, LBSIM Page 1


2/16

Submitted by -

Group 3

Abhilash Endigeri (127)

Madhurkant Gaur (12)

!a"hit #ane$a (13%)

&ragun 'anungo (1%)Aatish Mathur (12)

Akshay 'umar (17)

Mohit Gupta (132%13)

Contents

*ntrodu"tion 3

Production Planning4



3/16

Gla+oSmith'line pl" (GS') , An .er.ie/

About Crocin

9

Production Planning (Crocin Adance !""#g $ablet%&1"

Manu'acturing Proce%% (Batc %i)e* 1 Million $ablet%&12



4/16

1. Introduction

#he *ndian pharma"euti"als market is third largest in terms o0 .olume and thirteen largest in terms o0

.alue as per a pharma"euti"als se"tor analysis report by euity master #he market is dominated ma$orly

by branded generi"s /hi"h "onstitute nearly 7% to % per "ent o0 the market 4onsidered to be a highly

0ragmented industry"onsolidation has in"reasingly be"ome an important 0eature o0 the *ndian

pharma"euti"al market



5/16

*ndia has a"hie.ed an eminent global position in pharma se"tor #he "ountry also has a huge pool o0

s"ientists and engineers /ho ha.e the potential to take the industry to a .ery high le.el

#he 56-ba"ked Medi"ines &atents &ool has signed si+ sub-li"enses /ith Aurobindo 4ipla esano

Em"ure 8etero 9abs and 9aurus 9abs allo/ing them to make generi" anti-A*S medi"ine

#eno0o.irAla0enamide (#A:) 0or 112 de.eloping "ountries

#he *ndian &harma"euti"al market (*&M) is highly 0ragmented /ith about 2;%%% players (33% in the

organi=

?o?.s 12= in 2%13 #he gro/th /as impa"ted as the drug pri"e "ontrol order (&4) issued noti"e to

bring 3; drugs under pri"e "ontrol espite this the *ndian pharma market remains one o0 the 0astest

gro/ing pharma markets in the /orld 4urrently the *&M is third largest in terms o0 .olume and thirteen

largest in terms o0 .alue

@esides the domesti" market *ndian pharma "ompanies also ha.e a large "hunk o0 their re.enues "oming

0rom e+ports hile some are 0o"using on the generi"s market in the 5S Europe and semi-regulated

markets others are 0o"using on "ustom manu0a"turing 0or inno.ator "ompanies @iopharma"euti"als is

also in"reasingly be"oming an area o0 interest gi.en the "omple+ity in manu0a"ture and limited

"ompetition

*ntrodu"tion o0 G5:A (Generi" drug 5ser :ee A"t) in the 5S during Buly 2%12 too had a negati.e

impa"t on pharma "ompanies As per this A"t the generi" "ompanies are reuired to pay user 0ees to

5S:A 0or appli"ation o0 drugs and manu0a"turing 0a"ilities #his 0ee /ill be utili


6/16

tari00 rates and introdu"ed stri"t pri"e "ontrol regulation /ith the 17% rugs &ri"e 4ontrol rder #his

ga.e a boost to the *ndian pharma"euti"al industry

#!*&s the intelle"tual property "omponent o0 the 5ruguay round o0 the GA## #reaty ha.e gi.en rise to

an a"rimonious debate bet/een the de.eloped "ountries and less de.eloped "ountries (94s) @usiness

interests in the de.eloped /orld "laimed large losses 0rom the imitation and use o0 their inno.ations in

94s #hey also asserted that *&!s /ould bene0it the de.eloping "ountries by en"ouraging 0oreign

in.estment by enabling trans0er o0 te"hnology and greater domesti" resear"h and de.elopment (!C)

n the other side 94 go.ernments /ere /orried about the higher pri"es that stronger *&!s /ould entail

and about the harm that their introdu"tion might "ause to in0ant high te"h industries *ndia /as .ery

a"ti.ely in.ol.ed in opposing the #!*&s "omponent o0 the GA## agreement espe"ially the proposal 0or

produ"t patents on pharma"euti"al inno.ations *ndira Gandhi su""in"tly summed up the national

sentiment at the orld 8ealth Assembly in 12F #he idea o0 a better-ordered /orld is one in /hi"h

medi"al dis"o.eries /ill be 0ree o0 patents and there /ill be no pro0iteering 0rom li0e and death 6o/ that

*ndia has signed the treaty though most un/illingly it is "ommitted to introdu"ing pharma"euti"al

produ"t patents 2%%; a .alue analysis ie "ost-bene0it analysis o0 this mo.e is essential 0or *ndia

2. Production Planning

$ere are 'our %tage%, %tep%, tecni+ue% or e%%ential% in te proce%% o' production

planning and control

$e 'our %tage% or %tep% in production planning and control are*

1 -outing,

2 Sceduling,

3 .i%patcing, and

4 /ollo0up

Initial t0o %tep% ie -outing and Sceduling, relate to production planning La%t t0o

%tep% ie .i%patcing and /ollo0up, relate to production control o0 let% continue

our di%cu%%ion 'urter to under%tand eac %tep in detail

Group 3, LBSIM Page


7/16

1. Routing

-outing i% te 5r%t %tep in production planning and control

-outing can be de5ned a% te proce%% o' deciding te pat (route& o' 0or6 and te

%e+uence o' operation%

-outing 57e% in adance*

$e +uantit8 and +ualit8 o' te product

$e #en, #acine%, #aterial%, etc to be u%ed

$e t8pe, nu#ber and %e+uence o' #anu'acturing operation%, and

$e place o' production

In %ort, routing deter#ine% :at;,


8/16

$e #ain ob=ectie o' routing i% to deter#ine (57& te be%t and ceape%t %e+uence

o' operation% and to en%ure tat ti% %e+uence i% 'ollo0ed in te 'actor8

-outing gie% a er8 %8%te#atic #etod o' conerting ra0#aterial% into 5ni%ed

good% It lead% to %#oot and e@cient 0or6 It lead% to opti#u# utili)ation o'

re%ource% na#el8, #en, #acine%, #aterial%, etc It lead% to dii%ion o' labour Iten%ure% a continuou% o0 o' #aterial% 0itout an8 bac6trac6ing It %ae% ti#e and

%pace It #a6e% te 0or6 ea%8 'or te production engineer% and 'ore#en It a% a

great inuence on de%ign o' 'actor8% building and in%talled #acine%

So, routing i% an i#portant %tep in production planning and control Production

planning %tart% 0it it

2. Scheduling

Sceduling i% te %econd %tep in production planning and control It co#e% a'terrouting

Sceduling #ean% to*

/i7 te a#ount o' 0or6 to do

Arrange te di>erent #anu'acturing operation% in order o' priorit8

/i7 te %tarting and co#pleting, date and ti#e, 'or eac operation

Sceduling i% al%o done 'or #aterial%, part%, #acine%, etc So, it i% li6e a ti#etable

o' production It i% %i#ilar to te ti#etable, prepared b8 te rail0a8%

$i#e ele#ent i% gien %pecial i#portance in %ceduling $ere are di>erent t8pe% o'

%cedule% na#el8, Ma%ter %cedule, peration %cedule and .ail8 %cedule

Sceduling elp% #anu'acturer% to #a6e opti#u# u%e o' ti#e It %ee% tat eac

piece o' 0or6 i% %tarted and co#pleted at a certain predeter#ined ti#e It elp% to

co#plete te =ob %8%te#aticall8 and in ti#e It bring% ti#e coordination in

production planning All ti% elp% to delier te good% to te cu%to#er% in ti#e It

al%o eli#inate% te idle capacit8 It 6eep% labour continuou%l8 e#plo8ed

So, %ceduling i% an i#portant %tep in production planning and control It i% e%%ential

in a 'actor8, 0ere #an8 product% are produced at te %a#e ti#e

3. Dispatching

.i%patcing i% te tird %tep in production planning and control It i% te action,

doing or i#ple#entation %tage It co#e% a'ter routing and %ceduling

Group 3, LBSIM Page D


9/16

.i%patcing, generall8 #ean% %tarting te proce%% o' production It proide% te

nece%%ar8 autorit8 to %tart te 0or6 It i% ba%ed on route%eet% and %cedule

%eet%

.i%patcing include% te 'ollo0ing*

I%%ue o' #aterial%, tool%, 57ture%, etc, 0ic are nece%%ar8 'or actual

production

I%%ue o' order%, in%truction%, dra0ing%, etc 'or %tarting te 0or6

Maintaining proper record% o' te %tarting and co#pleting eac =ob on ti#e

Moing te 0or6 'ro# one proce%% to anoter a% per te %cedule

Starting te control procedure

-ecording te idle ti#e o' #acine%

.i%patcing #a8 be eiter centrali)ed or decentrali)ed*

1 Ender centrali)ed di%patcing, order% are i%%ued directl8 b8 a centrali)ed

autorit8

2 Ender decentrali)ed di%patcing, order% are i%%ued b8 te concerned

depart#ent

4. Follow-up

/ollo0up or e7pediting i% te la%t %tep in production planning and control It i% a

controlling deice It i% concerned 0it ealuation o' te re%ult%

/ollo0up 5nd% out and re#oe% te de'ect%, dela8%, li#itation%, bottlenec6%,

loopole%, etc in te production proce%% It #ea%ure% te actual per'or#ance and

co#pare% it to te e7pected per'or#ance It #aintain% proper record% o' 0or6,

dela8% and bottlenec6% Suc record% are u%ed in 'uture to control production

/ollo0up i% per'or#ed b8 F7pediter%; or Stoc6 Ca%er%;

/ollo0up i% nece%%ar8 0en production decrea%e% een 0en tere i% proper

routing and %ceduling Production #a8 be di%turbed due to brea6do0n% o'

#aciner8, 'ailure o' po0er, %ortage o' #aterial%, %tri6e%, ab%enteei%#, etc /ollo0

up re#oe% te%e di@cultie% and allo0% a %#oot production



10/16

.i%pen%ingproce%%(2r%& Granulationand.r8ing(1"r%& tableting(1r%& i(r&3. GlaxoSmithKline plc (GSK ) !n "#er#ie$

Gla+oSmith'line pl" (GS') in"orporated on e"ember > 1 is a health"are "ompany that resear"hes

and de.elops pharma"euti"als .a""ines and "onsumer health"are produ"ts #he 4ompany operates in t/o

segmentsF &harma"euti"als and Ha""ines and 4onsumer 8ealth"are *ts brands in"lude Sensodyne

&anadol 8orli"ks &olident &aradonta+ #ums E6 6iIuitin6i"orette Abre.a Jo.ira+ and

Aua0resh #he 4ompany has its presen"e in o.er 1% markets a net/ork o0 ; manu0a"turing sites in 3>"ountries and resear"h and de.elopment (!C) "enters in the 5nited 'ingdom the 5nited States

@elgium and 4hina #he 4ompany o/ns the biologi"al "on$ugation plat0orm

&harma"euti"als and Ha""ines

#he 4ompanyKs &harma"euti"als segment de.elops and makes medi"ines to treat a range o0 a"ute and

"hroni" diseases #he 4ompany engages in deli.ering produ"ts 0or respiratory disease and port0olio o0

mature produ"ts su"h as SeretideAd.air Hentolin and :lo.ent *t also in"ludes !el.ar@reo Ellipta

/hi"h is an inhaled "orti"osteroid (*4S) and long-a"ting beta2 agonist (9A@A) "ombinationD Anoro

Ellipta /hi"h is a long-a"ting mus"arini" antagonist (9AMA) and 9A@A dual bron"hodilatorD *n"ruse

Ellipta (9AMA) and Arnuity Ellipta (*4S) *t has respiratory produ"ts in its pipeline in"luding

mepoli


11/16

Ha""ines in"lude *n0anri+ (diphtheria and tetanus) 8epatitis !otari+ (rota.irus) and Syn0lori+

(pneumonia)

#he 4ompanyKs human immunode0i"ien"y .irus (8*H) business is managed through HiiH 8ealth"are

/hi"h is a spe"ialist "ompany in 8*H that it o/ns /ith &0i


12/16

#he 4ompany "ompetes /ith AbbHie Amgen Astra Jene"a @ayer @ristol-Myers Suibb Eli 9illy

Bohnson C Bohnson Mer"k C 4o 6o.artis 6o.o 6ordisk &0i


13/16

Crocin !""#g* PKCalu#iniu# bli%ter pac6% o' 1! $ablet%

'herapeutic indications

Analge%ic and Antip8retic

(. Production Planning )Crocin Ad!ance (**#g 'ablets+

A% di%cu%%ed earlier ti% proce%% inole% 4 %tep% ie -outing, Sceduling,

.i%patcing and /eedbac6

:e 0ill %tart te procedure 0it routing

-E$IG

a& $e +uantit8 and ualit8 o' Product

$o deter#ine te +uantit8 o' product re+uired, 0e ae to 5r%t e%ti#ate te de#and

o' te product :e ae %ale% data 'ro# IMS o' preiou% #ont% 0ic could be

u%ed to e%ti#ate te de#and o' ti% #ont

P-.EC

$

M$<

"?J2"1!

E

$EI$S

M$<

"J2"1!

E

$EI$S

M$<

"!J2"1!

E

$EI$S

M$<

"4J2"1!

E

$EI$S

M$<

"3J2"1!

E

$EI$S

M$<

"2J2"1!

E

$EI$SCrocin

!""#g

1!

$ablet% ,"",423 !,24,24 !,D1,3 !,94,31 ,33,D?2 ,1,1$otal

$ablet% 9",",34! ?D,3,9" D?,24,94! D9,14,?4" 9!,"D,"D" 99,24,24"

F%ti#ated de#and 'or Augu%t 0ould be aerage o' te preiou% %i7 #ont% %ale%

F%ti#ated %ale%N D99"34" O 3(!492D&N91!!12

b& Men, #acine and #aterial% to be u%ed

Generall8 in te PCB (Paranitrocloro ben)ene& route 'or paraceta#ol

production #anpo0er o' !" i% re+uired



14/16

Raw #aterials

-a0 #aterial re+uire#ent% 'or Paraceta#ol production*

Ba%i% * ne tonne o' Paraceta#ol

Para nitrocloro ben)ene (PCB& 12! tonneAcetic an8dride "? tonneAcetic acid "34 tonneCau%tic %oda "?! tonneIron po0der "3" tonne


15/16

,. anu$acturing Process )atch si/e0 1 illion

'ablets+

Dispensing Process

In ti% proce%% all te ra0 #aterial% are #i7ed in te #acine 0it rotating blade%and prepare a uni'or# #i7 $i% proce%% u%uall8 ta6e% 2 r%

ranulation and Dring

$e %tep% inoled in 0et granulation 0ere, :eiging, Mi7ing, Granulation,

Screening te da#p #a%%, .r8ing, .r8 %creening, Lubrication and Co#pre%%ion $i%

proce%% ta6e% appro7i#atel8 1" r%

'ableting

In ti% proce%% te dried #i7 i% conerted into tablet% u%ing te tableting #acine,

!"" #g in our ca%e $i% proce%% ta6e% nearl8 2 %i't% ie 1r%

Pacaging

$e tablet% are ten pac6aged into %trip% o' 1! tablet% eac $i% proce%% re+uire% D

r%

Sceduling Proce%%

a& /i7ing te a#ount o' 0or6

$e #ontl8 de#and i% 91, !!,12 tablet% o' crocin !""#g and proce%% 'orte production o' 1" lac% table% i% nearl8 3r% $i% proce%% a% to be

repeated ! ti#e% eer8 #ont to #eet te de#and

Group 3, LBSIM Page 1!


16/16

Ideal ti#e calculation

Macine 1!Dr%

Macine 2 2!r%

Macine 3 "r%

Macine 4 34r%


Date post:	20-Feb-2018
Category:	Documents
Upload:	mohit-gupta
View:	224 times
Download:	0 times

Group3_Production Planning for Pharmaceutical Company

Documents